Philadelphia College of Osteopathic Medicine, Sinai Hospital of Baltimore and Plano (Texas) Orthopaedics Sports Medicine and Spine Center researchers wrote the poster presenting the data.
The researchers analyzed data for patients who underwent inpatient TKA procedures between July 1, 2013 and June 30, 2014. The study compared 14,668 patients who received EXPAREL with 80,160 patients who received a standard analgesic regimen.
The researches presented the data at the American Academy of Orthopaedic Surgeons 2016 annual meeting in Orlando, Fla., from March 1 to March 5.
Here are five highlights:
1. EXPAREL is used for single-dose infiltration into the surgical site for postsurgical analgesia.
2. It combines bupivacaine with DepoFoam.
3. Patients receiving EXPAREL experienced about a half-day reduction in length of hospital stay, compared to standard analgesic patients.
4. Of the patients receiving EXPAREL, 73.2 percent were discharged directly home, compared to 66.6 percent of standard analgesic patients.
5. “The ability to recover at home, rather than in a short-term nursing facility or rehabilitation center, not only lends itself to favorable hospital economics, but also, importantly, toward a more comfortable patient recovery experience,” said Michael Mont, MD, director of the Center for Joint Preservation and Replacement at Sinai Hospital.
More articles on devices:
Medical Compression Systems unveils ActiveCare platform at AAOS meeting — 4 takeaways
Medacta showcases latest surgical innovations at AAOS meeting — 5 takeaways
EOS imaging’s spineEOS receives CE Mark: 5 takeaways
